Response to Botulinum Toxin Type-A in Patients with Refractory Chronic Migraine
Journal of Microbiota · 2024
DOI: 10.5812/jmb-143130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiota, 2024. Verfasst von Hamidreza Hematti und 2 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Due to its debilitating nature, refractory chronic migraine (RCM) is primarily associated with a poor quality of life. However, controversy remains regarding the efficacy and safety of botulinum toxin for treating RCM.
Objectives
The aim of this study was to investigate the efficacy of botulinum toxin type A (BTX-A) in patients with RCM.
Methods
In this retrospective cross-sectional study conducted between April 2016 and March 2021, RCM patients who were resistant to conventional therapies and received BTX-A injections were followed for 7 and 14 days after the injection. The outcome variables included the frequency, duration, and severity of migraine episodes, the need for painkillers, adverse events, and the patient's perceived improvement. Data were analyzed using SPSS.
Results
In total, 52 RCM patients with a mean age of 31.84 years participated, of whom 69.2% were female. The frequency of migraine episodes decreased from a baseline of 9.84 to 3.94 and 1.25 at 7 and 14 days after injection, respectively (P < 0.001). The duration of migraine episodes dropped from 3 hours at baseline to 1.74 and 1.17 hours at 7 and 14 days post-BTX-A injection, respectively (P < 0.001). The severity of migraines alleviated from 8.07 at baseline to 6.48 and 3.38 at the respective follow-up times (P < 0.001). The need for painkillers also decreased at follow-ups (P < 0.001). Males achieved better treatment outcomes regarding the frequency of migraine episodes and the need for medications compared to females following BTX-A treatment (P < 0.05). Frontotemporal and frontotemporal-occipital headache distributions showed fewer migraine episodes, shorter duration, less severity, and lower need for painkiller consumption compared to other migraine types (P < 0.05). The most common adverse event was localized pain (42.3%), followed by itching (25.0%). A considerable number of patients felt improvement.
Conclusions
According to our findings, BTX-A is a safe and well-tolerated treatment for patients with RCM. Validation of these results requires adequately precise studies investigating the effect of BTX-A in detail.
Zitieren
APA
Hematti, H., Izadi, S., & Molaei, A. (2024). Response to Botulinum Toxin Type-A in Patients with Refractory Chronic Migraine. Journal of Microbiota. https://doi.org/10.5812/jmb-143130
Vancouver
Hematti H, Izadi S, Molaei A. Response to Botulinum Toxin Type-A in Patients with Refractory Chronic Migraine. Journal of Microbiota. 2024. doi:10.5812/jmb-143130
BibTeX
@article{Hematti2024,
author = {Hematti, Hamidreza and Izadi, Shahrzad and Molaei, Amir},
title = {Response to Botulinum Toxin Type-A in Patients with Refractory Chronic Migraine},
journal = {Journal of Microbiota},
year = {2024},
doi = {10.5812/jmb-143130}
}
EUVIMED